**Author details**

Xiaohong Wang1,2,3

Address all correspondence to: wangxiaohong@tsinghua.edu.cn

1 Key Laboratory for Advanced Materials Processing Technology, Ministry of Education & Center of Organ Manufacturing, Department of Mechanical Engineering, Tsinghua Univer‐ sity, Beijing, P.R. China

2 Business Innovation Technology (BIT) Research Centre, School of Science and Technology, Aalto University, Aalto, Finland

3 State Key Laboratory of Materials Processing and Die & Mould Technology, Huazhong University of Science and Technology, Wuhan, P.R. China

## **References**

**16. Conclusion remarks**

138 Advances in Biomaterials Science and Biomedical Applications

**Acknowledgment**

**Author details**

Xiaohong Wang1,2,3

sity, Beijing, P.R. China

Aalto University, Aalto, Finland

a permanent template, or a drug delivery vihicle.

Biocompatible is a vital important aspect for an implantable biomaterial. Among the numer‐ ous types of host responses to a broad spectrum of biomaterials, those with no adverse or negative effects, such as, fibrous encapsulation, osteolysis, hyperplasia, and inflammation are among the most expectant ones. As advances are made in biomaterial science and tech‐ nology, new implants/medical devices will be continually explored, alternatives to conven‐ tional implants will become more and more effective, and hence more and more attractive. In an effort to provide the best clinical outcomes for the patients, we need to develop the best candidates with minimum invasive surgery times and unnecessary health risks. In the future, design and manufacture immuno or low-immuno implantable biomaterials accord‐ ing to or mimicking the patients' own ingredients, such as blood components, ECMs, tissues and organs, will be possible. For an implantable biomaterial biocompatibility should be al‐ ways put into the primary importance position no matter it is used as a temporary scaffold,

Work in the authors' laboratory is supported by the State Key Laboratory of Materials Proc‐ essing and Die & Mould Technology, Huazhong University of Science and Technology (No. 2012 - P03), the National Natural Science Foundation of China / the Research Grants Council of Hong Kong (NSFC/RGC, No. 50731160625), the National Natural Science Foundation of China (No. 81271665 & 30970748), the National High Tech 863 Grant (No. 2009AA043801), the Finland Distinguished Professor program (FiDiPro) of Tekes (No. 40041/10), and the

1 Key Laboratory for Advanced Materials Processing Technology, Ministry of Education & Center of Organ Manufacturing, Department of Mechanical Engineering, Tsinghua Univer‐

2 Business Innovation Technology (BIT) Research Centre, School of Science and Technology,

3 State Key Laboratory of Materials Processing and Die & Mould Technology, Huazhong

Cross-Strait Tsinghua Cooperation Basic Research (No.2012THZ02-3).

Address all correspondence to: wangxiaohong@tsinghua.edu.cn

University of Science and Technology, Wuhan, P.R. China


[30] en.wikipedia.org/wiki, the free encyclopedia.

[16] Hou ZQ, Sun Q, Wang Q, Han J, Wang Y, Zhang QQ. *In vitro* and *in vivo* evaluation of novel implantable collagen–chitosan–soybean phosphatidylcholine composite film

[17] Ward, A.G.; Courts, A. The Science and Technology of Gelatin. New York: Academic

[18] Kakiuchi M, Hosoya T, Takaoka K, Amitani K, Ono K. Human bone matrix gelatin as a clinical alloimplant. A retrospective review of 160 cases. Int Orthop 1985;9(3):

[19] Wang XH, Yan YN, Zhang RJ. Gelatin-based hydrogels for controlled cell assembly. In: Ottenbrite RM, ed. Biomedical Applications of Hydrogels Handbook. New York:

[20] Wang XH, Yan YN, Zhang RJ Rapid prototyping as a tool for manufacturing bioarti‐

[21] Wang XH, Yan YN, Zhang RJ. Recent trends and challenges in complex organ manu‐

[22] Wang XH, Zhang QQ. Overview on "Chinese–Finnish workshop on biomanufactur‐

[23] Wang XH. Intelligent freeform manufacturing of complex organs. Artificial Organs.

[24] Xu W, Wang XH, Yan YN, Zhang RJ. A polyurethane-gelatin hybrid construct for manufacturing implantable bioartificial livers. J Bioact Compat Polym 2008;23(5):

[25] He K, Wang XH. Rapid prototyping of tubular polyurethane and cell/hydrogel con‐

[26] Kimura Y, Ozeki M, Inamoto T, Tabata Y. Adipose tissue engineering based on hu‐ man preadipocytes combined with gelatin microspheres containing basic fibroblast

[27] Liu J. Controlled trans-lymphatic delivery of chemotherapy for the treatment of lym‐ phatic metastasis in lung cancer. A thesis submitted in conformity with the require‐ ments for the degree of Doctor of Philosophy Institute of Medical Science, University

[28] Ozeki M, Ishii T, Hirano Y, Tabata Y. Controlled release of hepatocyte growth factor from gelatin hydrogels based on hydrogel degradation. J Drug Target. 2001;9(6):

[29] Yang Z, Xu LS, Yin F, Shi YQ, Han Y, Zhang L, Jin HF, Nie YZ, Wang JB, Hao X, Fan DM, Zhou XM. *In vitro* and *in vivo* characterization of silk fibroin/gelatin composite

scaffolds for liver tissue engineering. J Dig Dis. 2012 Mar;13(3):168-178.

ing and evaluation techniques. Artificial Organs 2011;35(10):E191- E193.

for the sustained delivery of mitomycin C. Drug Dev Res 2009;70(3):169-219.

Press. 1977;ISBN0-12-735050-0.

140 Advances in Biomaterials Science and Biomedical Applications

Springer, 2010;269-284.

ficial livers. Trends Biotechnol 2007;25:505-513.

facturing. Tissue Eng Part B 2010;16:189-197.

2012; doi:10.1111/j.1525-1594.2012.01499.x.

struct. J Bioact Compat Polym 2011;26(4):363-374.

growth factor. Biomaterials 24 (2003) 2513–2521.

181-188.

409-422.

of Toronto, 2008.

461-471.


[46] Jeffrey M. Karp JM, Sarraf F, Shoichet MS, Davies JE. Fibrin-filled scaffolds for bonetissue engineering: An *in vivo* study. J Biomed Mater Res 2004;71A:162–171.

[47] Farhat WA, Chen J, Sherman C, Cartwright L, Bahoric A, Yeger H. Impact of fibrin glue and urinary bladder cell spraying on the in-vivo acellular matrix cellularization:

[48] Breen A, O'Brien T, and Pandit A. Fibrin as a Delivery System for Therapeutic Drugs

[49] Briganti E, Spiller D, Mirtelli C, Kull S, Counoupas C, Losi P, Senesi S, Di Stefano R, and Soldani G. A. Composite fibrin-based scaffold for controlled delivery of bioac‐

[50] Jockenhoevel S, Zund G, Hoerstrup SP, Chalabi K, Sachweh JS, Demircan L, Messm‐ er BJ, Turina M. Fibrin gel -- advantages of a new scaffold in cardiovascular tissue

[51] Catelas I, Dwyer JF, and Helgerson S. Controlled release of bioactive transforming growth factor Beta-1 from fibrin gels *in vitro*. Tissue Eng Part C Methods 2008;14(2):

[52] Arkudas A, Pryymachuk G, Hoereth T, Beier JP, olykandriotis E, Bleiziffer O, Horch RE, and Kneser U. Dose- Finding Study of Fibrin Gel-Immobilized Vascular Endo‐ thelial Growth Factor 165 and Basic Fibroblast Growth Factor in the Arteriovenous

[53] Breen A, O'Brien T, and Pandit A. Fibrin as a Delivery System for Therapeutic Drugs

[54] Sakiyama SE, Schense JC, and Hubbell JA. Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue

[55] Zisch AH, Schenk U, Schense JC, Sakiyama-Elbert SE, and Hubbell JA. Covalently conjugated VEGF—fibrin matrices for endothelialization. J Control Release

[56] Hara T. Bhayana B, Thompson B, Kessinger CW, McCarthy AKR, Weissleder R, Lin CP, Tearney GJ, Jaffer FA. Molecular Imaging of Fibrin Deposition in Deep Vein Thrombosis Using Fibrin-Targeted Near-Infrared Fluorescence. J Am Coll Cardiol

[57] Ruszymah BH. Autologous human fibrin as the biomaterial for tissue engineering.

[58] Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, Baigent C. Towards evidence-based guidelines for the prevention of venous thromboembolism: systemat‐ ic reviews of mechanical methods, oral anticoagulation, dextran and regional anaes‐ thesia as thromboprophylaxis. Health Technol Assess 2005;9(49):iii-iv, ix-x, 1-78.

tive pro-angiogenetic growth factors. J Control Release 2010;142(1):14-21.

a porcine pilot study. Can J Urol 2006;13(2):3000-3008.

142 Advances in Biomaterials Science and Biomedical Applications

and Biomolecules. Tissue Eng Part B Rev. 2009;15(2):201-214.

engineering. Eur J Cardiothorac Surg 2001;19(4):424-430.

Loop Rat Model. Tissue Eng Part A. 2009;15(9):2501-2511.

and Biomolecules. Tissue Eng Part B Rev 2009;15(2):201-214.

engineering. FASEB J. 1999;13(15):2214-2224.

Med J Malaysia 2004;59(Suppl B):30-31.

2001;72(1-3):101-113.

Img 2012;5:607–1551.

119-128.


[87] Chen WYJ, Giovanni Abatangelo G. Functions of hyaluronan in wound repair. Wound Repair and Regeneration 1999;7(2):79-89.

[73] Kahmann JD, O'Brien R, Werner JM, Heinegard D, Ladbury JE, Campbell ID, Day AJ. Localization and characterization of the hyaluronan-binding site on the Link

[74] Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anti‐ cancer drug conjugates. Bioorganic and Medicinal Chemistry 2005;13:5043–5054. [75] Paiva P, Van Damme MP, Tellbach M, Jones RL, Jobling T, Salamonsen LA. Expres‐ sion patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. Gynecologic Oncology

[76] Lokeshwar, VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N, Altman N. Antitumor activity of hyaluronic acid synthesis inhibitor 4 methylumbelliferone in prostate cancer cells. Cancer Res 2010;70(7):2613–2623. [77] Amarnath LP, Srinivas A, Ramamurthi A. *In vitro* hemocompatibility testing of UV-

[78] Jansen K., van der Werff JFA, van Wachem PB, Nicolai JPA, de Leij L.F.M.H, van Luyn MJA. A hyaluronan-based nerve guide: *in vitro* cytotoxicity, subcutaneous tis‐

[79] Rah MJ. A review of hyaluronan and its ophthalmic applications. Optometry

[80] De Andrés Santos MI, Velasco-Martín A, Hernández-Velasco E, Martín-Gil J, Martín-Gil FJ. Thermal behaviour of aqueous solutions of sodium hyaluronate from different

[81] Peattie RA, Rieke E, Hewett E, Fisher RJ, Shu XZ, Prestwich GD. Dual growth factorinduced angiogenesis *in vivo* using hyaluronan hydrogel implants.Biomaterials 2006;

[82] Pike DB, Cai S, Pomraning KR, Firpo MA, Fisher RJ, Shu XZ, Prestwich GD, Peattie RA. Heparin-regulated release of growth factors *in vitro* and angiogenic response *in vivo* to implanted hyaluronan hydrogels containing VEGF and Bfgf. Biomaterials

[83] Dianhua Jiang, Jiurong Liang, Paul W. Noble. Hyaluronan as an Immune Regulator

[84] Jiang DH, Liang JR, Noble PW. Hyaluronan in Tissue Injury and Repair. Annual Re‐

[85] Luke R. Bucci, Amy A. Turpin. Will the real hyaluronan please stand up? Journal of

[86] Longaker MT, Chiu ES, Adzick NS, Stem M, Harrison MR, Stem R. Studies in fetal wound healing: V. A prolonged presence of hyaluronic acid characterizes fetal

wound fluid. Annals of Surgery. Annals of Surgery 1991;213(4):292-296.

in Human Diseases. Physiol Rev January 1, 2011 vol. 91 no. 1 221-264.

view of Cell and Developmental Biology 2007;23:435-461.

sue reactions, and degradation in the rat. Biomaterials 2004;25(1):483–489.

modified hyaluronan hydrogels. Biomaterials 2006; 27(8):1416–1424.

commercial sources". Thermochim Acta 1994;42:153-160.

module from human TSG-6. Structure 2000;8:763–774.

144 Advances in Biomaterials Science and Biomedical Applications

2005;3:202.

2011;82(1):38-43.

27 (9):1868-1875,

2006;27(30):5242–5251.

applied nutrition 2004;54(1):10-33.


[116] Soon-Shiong P, Heintx RE, Merideth N, Yao QX, Yao Z, Zheng T, Murphy M, Molo‐ ney MK, Schmedhl M, Harris M, Mendez R, Mendez R, Sanford PA. The Lancet 1994;16:950-951.

[102] Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med. 2011;124(8):756-765. [103] Wang XH, Yan YN, Lin F, Xiong Z, Wu RD, Zhang RJ, Lu QP. Preparation and char‐ acterization of a collagen/chitosan/heparin matrix for an implantable bioartificial liv‐

[104] Yu X, Bichtelen A, Wang XH, Yan YN, Lin F, Xiong Z, Wu RD, Zhang RJ, Lu QP. Col‐ lagen/chitosan/heparin complex with improved biocompatibility for hepatic tissue

[105] Matthew D. Mitchell, Barbara Jo Anderson, Kendal Williams & Craig A. Umscheid. Heparin flushing and other interventions to maintain patency of central venous cath‐ eters: a systematic review. Journal of Advanced Nursing 2009;65(10), 2007–2021. [106] Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syn‐ drome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet

[107] Marcum JA, McKenney JB, Galli SJ, Jackman RW, Rosenberg RD. Anticoagulantly ac‐ tive heparin-like molecules from mast cell-deficient mice. Am J Physiol 1986;250 (5 Pt

[108] Nader HB, Chavante SF, dos-Santos EA, Oliveira FW, de-Paiva JF, Jerônimo SMB, Medeiros GF, de-Abreu LRD, Leite EL, de-Sousa-Filho JF, Castro RAB, Toma L, Ter‐ sariol ILS, Porcionatto MA, Dietrich CP. Heparan sulfates and heparins: similar com‐ pounds performing the same functions in vertebrates and invertebrates? Braz J Med

[109] Peattie RA, Rieke E, Hewett E, Fisher RJ, Shu X Z, Prestwich G D. Dual growth fac‐ tor-induced angiogenesis *in vivo* using hyaluronan hydrogel implants. Biomaterials

[110] Swanson JM. Heparin-induced thrombocytopenia: a general review. J Infus Nurs.

[111] Hong MS, Amanullah AM. Heparin-induced thrombocytopenia: a practical review.

[112] James L. Januzzi, Jr. and Ik-Kyung Jang. Heparin Induced Thrombocytopenia: Diag‐ nosis and Contemporary Antithrombin Management. J Thromb Thrombolysis

[113] Strand BL, Ryan L, Veld PI, Kulseng B, Rokstad AM, Skjåk-Bræk G., Especik T. Cell

[114] Yao R, Zhang RJ, Yan YN, Wang XH. *In vitro* angiogenesis of 3D tissue engineered

[115] Yao R, Zhang RJ, Wang XH. Design and evaluation of a cell microencapsulating de‐ vice for cell assembly technoloty. J Bioact Compat Polym 2009;24(1):48-62.

adipose tissue. J Bioact Compat Polym 2009;24(1):5-24.

er. J Biomater Sci.Polym Ed 2005;16(9):1063-1080.

Gynecol. 2010;115(6):1256-1262.

146 Advances in Biomaterials Science and Biomedical Applications

Biol Res 1999;32(5):529–538.

Rev Cardiovasc Med 2010;11(1):13-25.

2006;27(9):1868-1875.

2007;30(4):232-240.

1999;7:259–264.

Transplant. 2001;10:263-275.

2): H879–888.

engineering. J Bioact Compat Polym 2005;20(1):15-28.


[145] Sun J, Jiang G, Qiu T, Wang Y, Zhang K, Ding F. Injectable chitosan-based hydrogel for implantable drug delivery: body response and induced variations of structure and composition. J Biomed Mater Res A. 2010;95(4):1019-1027.

[131] Wang XH, Ma JB, Feng QL, Cui FZ. Skeletal repair in rabbits with calcium phosphate cements incorporated phosphorylated chitin. Biomaterials 2002;23(23):4591-4600.

[132] Wang XH, Ma JB, Feng QL, Cui FZ. *in vivo* evaluation of S-chitosan enhanced calci‐

[133] Wang XH, Feng QL, Cui FZ, Ma JB. The effects of S-chitosan on the physical proper‐ ties of calcium phosphate cements. J Bioact Compat Polym 2003;18(1):45-57.

[134] Liu H, Mao J, Yao K, Yang G, Cui L, Cao Y. A study on a chitosan-gelatin-hyaluronic acid scaffold as artificial skin *in vitro* and its tissue engineering applications. J Bio‐

[135] Fu LN, Wang W, Yu LJ, Zhang SM, Yang G. Fabrication of novel cellulose/chitosan artificial skin composite. Materials Science Forum 2009;610-613:1034-1038.

[136] Yussof SJM, Halim AS, Saad AZM, Jaafar H. Evaluation of the Biocompatibility of a Bilayer Chitosan Skin Regenerating Template, Human Skin Allograft, and Integra Implants in Rats. International Scholarly Research Network (ISRN) Materials Science

[137] Schulz III JT, Tompkins RG, Burke JF. Artificial Skin. Annual Review of Medicine

[138] Jebahi S, Oudadesse H, Bui XV, Keskes H, Rebai T, Feki A, Feki H. Repair of bone defect using bioglass-chitosan as a pharmaceutical drug: An experimental study in an ovariectomised rat model. African Journal of Pharmacy and Pharmacology 2012;

[139] Zhang Z, Cui HF. Biodegradability and Biocompatibility Study of Poly(Chitosan-g-

[140] Li XG, Yang ZY, Zhang AF, Wang TL, Chen WC. Repair of thoracic spinal cord in‐ jury by chitosan tube implantation in adult rats. Biomaterials 2009;30(6):1121–1132.

[141] Wang XH, Yan YN, Xiong Z, Lin F, Wu RD, Zhang RJ, Lu, QP. Preparation and Eval‐ uation of Ammonia Treated Collagen/Chitosan matrices for Liver Tissue Engineer‐

[142] Wang XH, Li DP, Wang WJ, Feng QL,Cui FZ, Xu YX, Song XH, van der Werf M. Crosslinked collagen/chitosan matrix for artificial livers, Biomaterials 2003;24(19):

[143] Wang XH, Cui FZ, Feng QL, Li JC, Zhang YH. Preparation and characterization of collagen/chitosan matrices as potential biomaterials. J Bioact Compat Polym

[144] Denkbas EB, Seyyal M, Piskin E. Implantable 5-fluorouracil loaded chitosan scaffolds prepared by wet spinning. Journal of Membrane Science 2000;172(1):33-38.

ing. J Biomed Mater Res Part B Appl. Biomater 2005;75B: 91-98.

lactic Acid) Scaffolds. Molecules 2012;17:3243-3258.

um phosphate cements. J Bioact Compat Polym 2003;18(4):259-271.

mater Sci Polym Ed 2004;15(1):25-40.

148 Advances in Biomaterials Science and Biomedical Applications

Volume 2011:1 -7.

2000;51:231-244.

6(16):1276-1287.

3213-3220.

2003;18(6):453-467.


[169] Corey JM, Gertz CC, Wang BS, Birrell LK, Johnson SL, Martin DC, Feldman EL. The design of electrospun PLLA nanofiber scaffolds compatible with serum-free growth of primary motor and sensory neurons. Acta Biomater 2008;4(4):863-875)

[157] Nagahama K, Ohya Y, Ouchi T. Synthesis of Star-shaped 8 arms Poly(ethylene gly‐ col)-Poly(L-lactide) Block Copolymer and Physicochemical Properties of Its Solution

[158] van der Lei B, Bartels HL, Nieuwenhuis P, Wildevuur CR. Microporous, complaint, biodegradable vascular grafts for the regeneration of the arterial wall in rat abdomi‐

[159] Middleton J; Tipton A. Synthetic biodegradable polymers as medical devices". Medi‐

[160] Muhonen J, Suuronen R, Oikarinen VJ, Sarkiala E, Happonen R-P. Effect of polygly‐ colic acid (PGA) membrane on bone regeneration around titanium implants inserted in bone sockets. Journal of Materials Science: Materials in Medicine 1994; 5(1):40-42.

[161] Taylor MS, Daniels AU, Andriano KP, Heller J. Six bioabsorbable polymers: *in vitro* acute toxicity of accumulated degradation products. J Appl Biomater 1994;5(2):

[162] Anderson JM. Biological responses to materials. Annu Rev Mater Res. 2001;31:81–

[163] van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circula‐

[164] Venkatraman S, Boey YC. Patent: Implantable article, method of forming same and method for reducing thrombogenicity. IPC8 Class: AA61F206FI, USPC Class: 623001440, Publication date: 2012-07-12, Patent application number: 20120179242.

[165] Bhardwaj U, Papadimitrakopoulos F, Burgess DJ. A review of the development of a vehicle for localized and controlled drug delivery for implantable biosensors. J Dia‐

[166] Onuki Y, Bhardwaj U, Burgess PDJ. A Review of the Biocompatibility of Implantable Devices: Current Challenges to Overcome Foreign Body Response. J Diabetes Sci

[167] Bhardwaj U, Sura R, Papadimitrakopoulos F, Burgess DJ. Controlling acute inflam‐ mation with fast releasing dexamethasone-PLGA microsphere/PVA hydrogel com‐ posites for implantable devices. Journal of Diabetes Science and Technology

[168] Ranganath SH, Yang A, Chan YY, Huang J, Krantz WB, Wang CH. Implantable hy‐ drogel beads entrapping PLGA-paclitaxel microspheres: exploring the effects of near-zero order drug release for intracranial chemotherapy. AIChE Annual meeting,

Cast Film as Soft Biomaterial. Polymer Journal 2006;38:852–860.

cal Plastics and Biomaterials Magazine. 1998 Retrieved 2006-07-04.

nal aorta. Surgery. 1985 Nov;98(5):955-963.

150 Advances in Biomaterials Science and Biomedical Applications

151-157.

tion. 1996;94(7):1690–1697.

betes Sci Technol. 2008;2(6):1016-1029.

Philadelphia, USA, November 2008.

Technol 2008;2(6):1003-1015.

2007;1(1):8-17.

110.


[196] Yan YN, Wang XH, Yin DZ, Zhang RJ. A new polyurethane/heparin vascular graft for small-caliber vein repair. J Bioact Compat Polym 2007;22(3):323-341.

[184] Hauser RG, Cannom D, Hayes DL, Parsonnet V, Hayes J, Ratliff N 3rd, Tyers GF, Ep‐ stein AE, Vlay SC, Furman S, Gross J. Long-term structural failure of coaxial polyur‐ ethane implantable cardioverter defibrillator leads. Pacing Clin Electrophysiol.

[185] Stokes KB, Church T. Ten-year experience with implanted polyurethane lead insula‐

[186] Santerre JP, Woodhouse K, Laroche G, Labow RS. Understanding the biodegradation of polyurethanes: From classical implants to tissue engineering materials. Biomateri‐

[187] Wang Y. Patent: Implantable Medical Devices Fabricated From Polyurethanes With Grafted Radiopaque Groups. IPC8 Class: AA61F282FI, USPC Class: 623 134, Class name: Prosthesis (i.e., artificial body members), parts thereof, or aids and accessories therefor arterial prosthesis (i.e., blood vessel) having marker (e.g., color, radiopaque,

etc.), Publication date: 2009-10-15, Patent application number: 20090259297

[188] Stachelek SJ, Alferiev I, Connolly JM, Sacks M, Hebbel RP, Bianco R, Levy RJ. Choles‐ terol-modified polyurethane valve cusps demonstrate blood outgrowth endothelial cell adhesion post-seeding *in vitro* and *in vivo*. Ann Thorac Surg. 2006 Jan;81(1):47-55.

[189] Ghanbari H, Viatge H, Kidane AG, Burriesci G, Tavakoli M, Seifalian AM. Polymeri‐ ca heart valves: new materials, emerging hopes. Trends in Biotechnology 2009;27(6):

[190] Gwendolyn M.R. Wetzels, Leo H. Koole. Photoimmobilisation of poly(N-vinylpyrro‐ lidinone) as a means to improve haemocompatibility of polyurethane biomaterials.

[191] Staniszewska-Kuś J, Paluch D, Krzemień-Dabrowska A, Zywicka B, Solski L.Tissue reaction to implanted polyurethane designed for parts of the artificial heart. Polym

[192] Stachelek SJ, Alferiev I, Choi H, Chan CW, Zubiate B, Sacks M, Composto R, Chen I-W, Levy R. Prevention of oxidative degradation of polyurethane by covalent attach‐ ment of di-tert-butylphenol residues. J Biomed Mater Res A. 2006;78(4):653-661).

[193] Stachelek SJ, Alferiev I, Connolly JM, Sacks M, Hebbel RP, Bianco R, Levy RJ. Choles‐ terol-modified polyurethane valve cusps demonstrate blood outgrowth endothelial cell adhesion post-seeding in vitro and *in vivo* Ann Thorac Surg. 2006 Jan; 81(1):47-55.

[194] Alferiev I, Stachelek SJ, Lu ZB, Fu AL, Tiffany L. Sellaro TL, Jeanne M. Connolly JM, Richard W. Bianco RW, Michael S. Sacks MS, Robert J. Levy RJ. Prevention of polyur‐ ethane valve cusp calcification with covalently attached bisphosphonate diethylami‐

[195] Chris Smith. Implantable PU developer wins heart valve patent. Time:2009-08-03.

no moieties. J Biomed Mater Res A. 2003; 66(2):385-395.

tion. Pacing Clin Electrophysiol. 1986;;9(6 Pt 2):1160-1165.

2002;25(6):879-882.

152 Advances in Biomaterials Science and Biomedical Applications

als 2005;26(35):7457-7470.

Biomaterials 1999;20(20):1879}-1887.

Med. 1995;25(3-4):3-18.

359-367.


[223] Sedrakyan A, Normand ST, Dabic S, Jacobs S, Graves S, Marinac-Dabic D. Compara‐ tive assessment of implantable hip devices with different bearing surfaces: systemat‐ ic appraisal of evidence. BMJ 2011;343:d7434-7446.

[210] Danckwerts M, Fassihi A. Implantable Controlled Release Drug Delivery Systems: A

[211] Shakhashiri BZ. Chemical of the Week: Aluminum. SciFun.org. University of Wis‐ consin. http://scifun.chem.wisc.edu/chemweek/PDF/Aluminum.pdf. Retrieved

[212] Takami Y, Yamane S, Makinouchi K, Niimi Y, Sueoka A, Nosé Y. Evaluation of plate‐ let adhesion and activation on materials for an implantable centrifugal blood pump

[214] Tseung ACC, King WJ, Wan BYC. An encapsulated, implantable metal-oxygen cell as a long-term power source for medical and biological applications. Medical and Bio‐

[215] Stieglitz T. Flexible biomedical microdevices with double-sided electrode arrange‐ ments for neural applications. Sensors and Actuators A 2001;90:202-211.

[216] Jiang GQ, Mishler D, Davis R, Mobley JP, Schulman JH. Zirconia to Ti-6Al-4V braze joint for implantable biomedical device. J Biomed Mater Res Part B: Appl Biomater

[217] Dowling RD, Park SJ, Pagani FD, Mohr F-W. HeartMate VE LVAS design enhance‐ ments and its impact on device reliability. European Journal of Cardio-Thoracic Sur‐

[218] Takami Y, Yamane S, Makinouchi K, Niimi Y, Sueoka A, Nosé Y. Evaluation of plate‐ let adhesion and activation on materials for an implantable centrifugal blood pump.

[219] Spiliopoulos K, Giamouzis G, Karayannis G, Karangelis D, Koutsias S, Kalogeropou‐ los A, Georgiopoulou V, Skoularigis J, Butler J, Triposkiadis F. Current Status of Me‐ chanical Circulatory Support: A Systematic Review. Cardiology Research and

[220] Myllymaa S. Novel micro- and nano-technological approaches for improving the performance of implantable biomedical devices. Publications of the University of Eastern Finland. Dissertations in Forestry and Natural Sciences. University of East‐

[221] Olga L; Péter B; George KS; Jósef B. Porous hydroxyapatite and aluminium-oxide ce‐ ramic orbital implant evaluation using CBCT scanning: a method for *in vivo* porous structure evaluation and monitoring. International Journal of Biomaterials 2012; 1-9:

[222] Mitsuo A, Aizawa T. Thermal oxidation and characterization for surface layers of Al implanted TiN films. Ion Implantation Technology Proceedings, 1988 International

Conference on IEEE. Date of Conference: Dec 1999;2:865–868.

Practice 2012, Article ID 574198, 12 pages, doi:10.1155/2012/574198.

Review. 1991;17(11):1465-1502.

154 Advances in Biomaterials Science and Biomedical Applications

2012-03-04 (17 March 2008).

2005;72B: 316–321.

ern Finland. P122.

1687-8787.

gery 2004; 25(6):958–963.

Artif Organs 1998;22(9):753-758.

1. Artif Organs 1998;;22(9):753-758. [213] Polmear IJ. Light Alloys, Arnold, 1995.

logical Engineering and Computing 1971;9(3):175-184.


**Chapter 6**
